Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.

Trial Details

NCT ID
NCT07367516
Phase
PHASE1 / PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • TQB6411 Injection
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance.
  • Age between 18 and 75 years old (inclusive)
  • Eastern Cooperative Oncology Group (ECOG) score of 0-1
  • Expected survival \>12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →